Accord Buy To Let has launched a significant number of competitive 2-year fixed rate mortgages and reduced rates by up to 0.20% on some 3-year options.
Landlords requiring 60% loan-to-value can now opt for a 2-year fixed rate of 1.72% which comes with free standard valuation and product fee of £1,495.
Chris Maggs, commercial manager at Accord Buy To Let, said: “We constantly review our mortgage range and believe these new products will be welcome by brokers whose clients are looking for choice and flexibility when managing their portfolio.
“Our competitive short-term rates, coupled with the ability for borrowers to leave tracker deals without any early repayment charges could prove popular for landlords unsure of how the next few years will affect their portfolios and who value the ability to make changes without penalty.”
Those remortgaging can also take advantage of free legal fees, or anyone extending their portfolio can get £250 cashback on completion.
The lender is also offering £1,000 cashback to landlords remortgaging or extending their portfolio with a 2-year fixed rate of 2.89% at 75% LTV. This mortgage comes with a low fee of £195 and free standard valuation.
And 3-year fixed rates have also been reduced by up to 0.20%, with landlords who have a 25% deposit now able to choose a rate of 2.72%, which comes with free standard valuation and £500 cashback on completion.
Adding more choice to the range, Accord has also launched two new tracker mortgages with no early repayment charges (ERCs).
The mortgages track the Bank of England base rate, and are designed to provide landlords with flexibility to exit their mortgage early without paying an ERC should their circumstances change over the next two years.
At 75% loan-to-value (LTV) there is a 2.29% 2-year tracker which is available to those extending their portfolio, or remortgaging. Both mortgages have a product fee of £950 and include free standard valuation.
End dates have also been extended across the lender’s range, meaning landlords can benefit from current rates until March 2024.